Search All News
Researchers at the Gabriele Bartoli Brain Tumor Laboratory explain their findings leveraging a specific dietary approach to improve survival rates in glioblastoma patients.
Dr. Izar has been selected as a recipient of the Pershing Sohn Prize in recognition of his innovative approach to finding a new therapeutic target for brain metastasis.
Dr. Gill is focused on improving therapies for patients with brain cancer and shares why building thoughtful mentor-mentee relationships are critical in science and medicine.
- January 9, 2023
Translational scientist Robert Wechsler-Reya, PhD, an expert in pediatric brain cancer, has joined the Herbert Irving Comprehensive Cancer Center as scientific director of Brain Tumor Research.
Source:CUIMC NewsroomNovember 10, 2022
Dr. Jeffrey Bruce: "This new approach has the potential to transform treatment for patients with brain cancer, where the outlook for survival remains very poor."
- June 30, 2022
Three multi-disciplinary research teams have been awarded the 2022 Irving Multi-PI Planning Grant to fuel innovative research and treatment.
Source:NRG OncologyJune 28, 2022
Dr. Andrew Lassman: "These trials transformed our understanding of the clinical behavior of molecularly defined gliomas and contributed to the classification of gliomas used globally today."
- March 28, 2022
A new study led by Dr. Andrew Lassman addresses safety and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR)-tyrosine kinase inhibitor, for patients with recurrent glioblastomas.
- July 8, 2021
New clinical trial studies the application of focused ultrasound technique to deliver chemotherapy in patients with DIPG, an aggressive type of brain cancer.
Source:CUIMC NewsroomJanuary 11, 2021
A study, led by HICCC members, has found that up to 20% of glioblastomas—an aggressive brain cancer—are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.